Canada markets closed

Caladrius Biosciences, Inc. (CLBS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2000-0.0200 (-1.64%)
At close: 4:00PM EDT
1.2200 +0.02 (+1.67%)
After hours: 07:11PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.2200
Open1.1900
Bid1.1900 x 900
Ask1.2200 x 1000
Day's Range1.1600 - 1.2200
52 Week Range1.1200 - 4.8900
Volume421,235
Avg. Volume288,873
Market Cap71.421M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.7010
Earnings DateNov. 03, 2021 - Nov. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    Caladrius Biosciences Announces Participation in Upcoming Conferences in October 2021

    BASKING RIDGE, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: UK Kidney Week® Virtual Conference (October 4-7, 2021)Location: VirtualSession Title: Discovering Effective New Targets for Therapy in Kidney DiseaseSession Date/Time: Mond

  • GlobeNewswire

    Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15,

  • GlobeNewswire

    Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

    BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company’s Chief Medical Officer (“CMO”). Dr. Buck joins Caladrius from ICON plc (“ICON”), a global provider of drug and device development and commercialization services to the pharmac